Lilly (Eli) (LLY) fundamentals: P/E, valuation, undervalued?
Lilly (Eli) · Health Care · ref. ETF XLV · price $1176.1
In short — Lilly (Eli) trades at 40.0× earnings (P/E), 24.9× forward, with a net margin of 33.5 % and revenue growth of +48 %. Read: Cheap for the growth (P/E 25 for ~26% growth (PEG 1.0)).
Is Lilly (Eli) stock cheap or undervalued? A good time to buy? Here are its fundamentals — P/E, PEG, margin and income statement — to judge its valuation.
📈 1-year price
$1176.1+60.7% over range
Aug 28, 25low $714.59 · high $1280.34Aug 27, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
94% recommend buying · 16 analysts
Valuation : Cheap for the growth — P/E 25 for ~26% growth (PEG 1.0)
Valuation
40.0
P/E (price/earnings)
24.9
Forward P/E
1.53
PEG
30.9
Price/book (P/B)
$1.05T
Market cap
29.40
EPS
Profitability & growth
33.5 %
Net margin
+48 %
Revenue growth
+26 %
Earnings growth
$54.9B
Total debt
Lilly (Eli) income statement
| Fiscal year | Revenue | Net income | Margin |
|---|---|---|---|
| 2022 | $28.5B | $6.2B | 21.9 % |
| 2023 | $34.1B | $5.2B | 15.4 % |
| 2024 | $45.0B | $10.6B | 23.5 % |
| 2025 | $65.2B | $20.6B | 31.7 % |
⚠️ Indicative financial data (Yahoo Finance), not investment advice. Amounts in $.
Frequently asked questions
What is Lilly (Eli)'s P/E and is the stock undervalued? What's a good P/E?
Lilly (Eli)'s P/E is 40.0 (forward 24.9). Below ~15 = fairly cheap, above ~30 = expensive. Our valuation verdict: "Cheap for the growth".
Is Lilly (Eli) profitable?
Lilly (Eli) has a net margin of 33.5 % (EPS 29.40). The company is profitable.
Is LLY stock expensive?
Our read: "Cheap for the growth" — P/E 25 for ~26% growth (PEG 1.0). Cross-check with growth and sector.
💬 A question about Lilly (Eli)? The JPI assistant answers using our backtest data.